Given that the contribution of epigenetic silencing WIF1 to breast tumorigenesis as reported in the previous study [44], it is likely that the loss of methylation in the hypo-ER-positive cancer samples will suppress disease acceleration, which was also supported by the association between its expression and patients’ chances of survival (Fig. 6h). The gene discussed is ESR1; the disease is cancer.